Recon: European Patent Office invalidates Moderna mRNA patent; Nvidia and Genentech ink AI deal

• Delay of eye drop recall highlights FDA’s impotence on the issue (STAT)
• FDA warns against using Cardinal's syringes (Reuters)
• Going to 11: New Subsections at CDER’s Office of Pharmaceutical Quality Are Important Piece of FDA’s Inspection and Enforcement Strategy (FDA Law Blog)
• ‘Essential’ Drug Coverage Including Obesity Treatments Make Sense For ACA Plans, CMS Says (Pink Sheet)
• Confirmatory Trials: Comprehensive Development Plan, Early Communication Will Help Reduce Delays, US FDA Says (Pink Sheet)
• With filing in Sanofi and Mylan insulin lawsuit, FTC amps up scrutiny on pharma’s patent tactics (Fierce Pharma)

• UK's NHS hands U.S.-based Palantir contract for patient data software (Reuters)
• Flagship launches first UK-based startup to uncover genes that make cells vulnerable or resistant to disease (Endpoints)
• European Patent Office declares Moderna mRNA patent invalid (Reuters)
• BeiGene to buy global rights to Ensem's experimental cancer therapy (Reuters)
• Indian researchers find no link between sudden death and COVID shots (Reuters)
• Hemgenix: European Countries Start Joint HTA Of Another Costly Gene Therapy (Pink Sheet)
• Australia’s TGA Offers Drug Sponsors Better Access To Adverse Event Data (Pink Sheet)

• Bayer’s new CEO was dealt a duo of ‘clearing events.’ Tough choices lie ahead (STAT)
• Flagship Pioneering launches Quotient, a new biotech, in two countries (STAT)
• Mixed study results for MorphoSys blood-cancer drug raise questions about approval (STAT)
• Novo rations Ozempic starter kits amid surge in use for weight loss (Reuters)
• Updated: Merck commits up to $610M to buy out preclinical biotech and its neurodegenerative disease work (Endpoints)
• Alto Neuroscience closes $45M round; Simcere partners with Connect; Myricx licenses WuXi antibody (Endpoints)
• MorphoSys marches ahead with plans to file myelofibrosis drug despite mixed PhIII results (Endpoints)
• Former college roommates combine health and tech backgrounds to raise $58M for new fund (Endpoints)

• How the CEO of the largest medical device accelerator molds medtech startups (STAT)
• GSK boosts low-carbon inhaler development with PhIII trials, investment in French manufacturing facility (Endpoints)
• Medtronic shrugs off concerns over newer weight-loss drugs to raise annual forecast (Reuters)
• Nvidia signs deal with Genentech to pair drugmaker's machine learning with chip supplier's tech (Endpoints)
• Visana Health To Scale Virtual Women’s Health Clinic To Provide ‘Whole Human Being’ Care (MedTech Insight)

• Texas AG sues Pfizer over quality-control lapses in kids’ ADHD drug (Reuters)
• Premarket Dose Optimization Precedent In Oncology Likely Not Available Yet (Pink Sheet)
• Teva granted pretrial appeal in high-stakes Copaxone kickbacks case (Fierce Pharma)